Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept
Description: A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. This conversation explores the single unsuccessful trial result accompanying the spate of positive reports. Intercept’s REVERSE study focuses on evaluating the safety and efficacy of obeticholic acid (OCA) in patients with compensated cirrhosis. Stephen Harrison outlines the Phase 3 results which, ultimately, did not meet its primary endpoint. Stephen notes the analysis of the F3 REGENERATE trial continues and data from REVERSE may provide support for the REGENERATE safety story. Louise Campbell takes optimistic interest in...